. Safety, tolerability and pharmacokinetics of SUVN-502 - A 5-HT6 receptor antagonist, first in human phase-1 Single Ascending Dose (SAD) study. July 2009, Volume 5, Issue 4, Supplement, Page P250

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.